Stephen W Patrick1, Judith Dudley2, Peter R Martin3, Frank E Harrell4, Michael D Warren5, Katherine E Hartmann6, E Wesley Ely7, Carlos G Grijalva8, William O Cooper9. 1. Departments of Pediatrics, Mildred Stahlman Division of Neonatology, Vanderbilt University, Nashville, Tennessee; Vanderbilt Center for Health Services Research, Nashville, Tennessee; Health Policy, stephen.patrick@vanderbilt.edu. 2. Health Policy. 3. Psychiatry, Pharmacology. 4. Biostatistics. 5. Tennessee Department of Health, Nashville, Tennessee; and. 6. Vanderbilt Center for Health Services Research, Nashville, Tennessee; Obstetrics and Gynecology, and. 7. Vanderbilt Center for Health Services Research, Nashville, Tennessee; Medicine, Vanderbilt University, Nashville, Tennessee; Veteran's Affairs, Tennessee Valley Geriatric Research Education Clinical Center, Nashville, Tennessee. 8. Vanderbilt Center for Health Services Research, Nashville, Tennessee; Health Policy, Veteran's Affairs, Tennessee Valley Geriatric Research Education Clinical Center, Nashville, Tennessee. 9. Departments of Pediatrics, Vanderbilt Center for Health Services Research, Nashville, Tennessee; Health Policy.
Abstract
BACKGROUND AND OBJECTIVES: Although opioid pain relievers are commonly prescribed in pregnancy, their association with neonatal outcomes is poorly described. Our objectives were to identify neonatal complications associated with antenatal opioid pain reliever exposure and to establish predictors of neonatal abstinence syndrome (NAS). METHODS: We used prescription and administrative data linked to vital statistics for mothers and infants enrolled in the Tennessee Medicaid program between 2009 and 2011. A random sample of NAS cases was validated by medical record review. The association of antenatal exposures with NAS was evaluated by using multivariable logistic regression, controlling for maternal and infant characteristics. RESULTS: Of 112,029 pregnant women, 31,354 (28%) filled ≥ 1 opioid prescription. Women prescribed opioid pain relievers were more likely than those not prescribed opioids (P < .001) to have depression (5.3% vs 2.7%), anxiety disorder (4.3% vs 1.6%) and to smoke tobacco (41.8% vs 25.8%). Infants with NAS and opioid-exposed infants were more likely than unexposed infants to be born at a low birth weight (21.2% vs 11.8% vs 9.9%; P < .001). In a multivariable model, higher cumulative opioid exposure for short-acting preparations (P < .001), opioid type (P < .001), number of daily cigarettes smoked (P < .001), and selective serotonin reuptake inhibitor use (odds ratio: 2.08 [95% confidence interval: 1.67-2.60]) were associated with greater risk of developing NAS. CONCLUSIONS: Prescription opioid use in pregnancy is common and strongly associated with neonatal complications. Antenatal cumulative prescription opioid exposure, opioid type, tobacco use, and selective serotonin reuptake inhibitor use increase the risk of NAS.
BACKGROUND AND OBJECTIVES: Although opioid pain relievers are commonly prescribed in pregnancy, their association with neonatal outcomes is poorly described. Our objectives were to identify neonatal complications associated with antenatal opioid pain reliever exposure and to establish predictors of neonatal abstinence syndrome (NAS). METHODS: We used prescription and administrative data linked to vital statistics for mothers and infants enrolled in the Tennessee Medicaid program between 2009 and 2011. A random sample of NAS cases was validated by medical record review. The association of antenatal exposures with NAS was evaluated by using multivariable logistic regression, controlling for maternal and infant characteristics. RESULTS: Of 112,029 pregnant women, 31,354 (28%) filled ≥ 1 opioid prescription. Women prescribed opioid pain relievers were more likely than those not prescribed opioids (P < .001) to have depression (5.3% vs 2.7%), anxiety disorder (4.3% vs 1.6%) and to smoke tobacco (41.8% vs 25.8%). Infants with NAS and opioid-exposed infants were more likely than unexposed infants to be born at a low birth weight (21.2% vs 11.8% vs 9.9%; P < .001). In a multivariable model, higher cumulative opioid exposure for short-acting preparations (P < .001), opioid type (P < .001), number of daily cigarettes smoked (P < .001), and selective serotonin reuptake inhibitor use (odds ratio: 2.08 [95% confidence interval: 1.67-2.60]) were associated with greater risk of developing NAS. CONCLUSIONS: Prescription opioid use in pregnancy is common and strongly associated with neonatal complications. Antenatal cumulative prescription opioid exposure, opioid type, tobacco use, and selective serotonin reuptake inhibitor use increase the risk of NAS.
Authors: William O Cooper; Sonia Hernandez-Diaz; Patrick G Arbogast; Judith A Dudley; Shannon Dyer; Patricia S Gideon; Kathi Hall; Wayne A Ray Journal: N Engl J Med Date: 2006-06-08 Impact factor: 91.245
Authors: Brian J Cleary; Jean Donnelly; Judith Strawbridge; Paul J Gallagher; Tom Fahey; Mike Clarke; Deirdre J Murphy Journal: Addiction Date: 2010-09-15 Impact factor: 6.526
Authors: Faouzi I Maalouf; William O Cooper; Shannon M Stratton; Judith A Dudley; Jean Ko; Anamika Banerji; Stephen W Patrick Journal: Pediatrics Date: 2018-12-04 Impact factor: 7.124
Authors: Amie J Goodin; Joshua D Brown; Chris Delcher; Patricia R Freeman; Jeffery Talbert; Stephen G Henry; Dikea Roussos-Ross Journal: Res Social Adm Pharm Date: 2019-03-26
Authors: Constance Guille; Kelly S Barth; Julio Mateus; Jenna L McCauley; Kathleen T Brady Journal: Am J Psychiatry Date: 2017-03-01 Impact factor: 18.112
Authors: Susan M Lopata; Elizabeth McNeer; Judith A Dudley; Carolyn Wester; William O Cooper; James G Carlucci; Claudia M Espinosa; William Dupont; Stephen W Patrick Journal: Pediatrics Date: 2020-02-14 Impact factor: 7.124
Authors: Christiana N Oji-Mmuo; Eric J Michael; Jacqueline McLatchy; Mary M Lewis; Julie E Becker; Kim Kopenhaver Doheny Journal: Acta Paediatr Date: 2015-12-23 Impact factor: 2.299